{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:38:00Z","timestamp":1793036280287,"version":"4.5.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018 in the international prospective T-cell Project (NCT01142674). The primary and secondary end points were 5-year overall survival (OS) and progression-free survival (PFS), respectively. We analyzed the prognostic impact of clinical covariates and progression of disease within 24 months (POD24) and developed a novel prognostic score. The median age was 64 years, and 90% of patients had advanced-stage disease. Eighty-one percent received anthracycline-based regimens, and 13% underwent consolidative autologous stem cell transplant (ASCT) in first complete remission (CR1). Five-year OS and PFS estimates were 44% and 32%, respectively, with improved outcomes for patients who underwent ASCT in CR1. In multivariate analysis, age \u226560 years, Eastern Cooperative Oncology Group performance status &amp;gt;2, elevated C-reactive protein, and elevated \u03b22 microglobulin were associated with inferior outcomes. A novel prognostic score (AITL score) combining these factors defined low-, intermediate-, and high-risk subgroups with 5-year OS estimates of 63%, 54%, and 21%, respectively, with greater discriminant power than established prognostic indices. Finally, POD24 was a powerful prognostic factor with 5-year OS of 63% for patients without POD24 compared with only 6% for patients with POD24 (P &amp;lt; .0001). These data will require validation in a prospective cohort of homogeneously treated patients. Optimal treatment of AITL continues to be an unmet need, and novel therapeutic approaches are required.<\/jats:p>","DOI":"10.1182\/blood.2020010387","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T22:56:46Z","timestamp":1617145006000},"page":"213-220","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":139,"title":["Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project"],"prefix":"10.1182","volume":"138","author":[{"given":"Ranjana H.","family":"Advani","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2276-869X","authenticated-orcid":false,"given":"Tetiana","family":"Skrypets","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance (CHIMOMO), University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8606-5806","authenticated-orcid":false,"given":"Monica","family":"Civallero","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance (CHIMOMO), University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Spinner","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Manni","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance (CHIMOMO), University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[{"name":"Division of Hematology, Fred Hutchinson Cancer Research Center, University of Washington Medical Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Hitz","sequence":"additional","affiliation":[{"name":"The Swiss Group for Clinical Cancer Research, Department of Oncology\/Haematology, Cantonal Hospital, St Gallen, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Cabrera","sequence":"additional","affiliation":[{"name":"Secci\u00f3n Hematolog\u00eda, Hospital del Salvador, Universidad de Chile, Santiago, Chile;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Dlouhy","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Clinic de Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-4865","authenticated-orcid":false,"given":"Jos\u00e9","family":"Vassallo","sequence":"additional","affiliation":[{"name":"A.C. Camargo Cancer Center, Universidade Estadual de Campinas (Unicamp), Campinas, S\u00e3o Paulo, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-5128","authenticated-orcid":false,"given":"Stefano A.","family":"Pileri","sequence":"additional","affiliation":[{"name":"Division of Haematopathology, Istituto Europeo di Oncologia Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5566-0864","authenticated-orcid":false,"given":"Giorgio","family":"Inghirami","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-9725","authenticated-orcid":false,"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[{"name":"Department of Haemato-oncology, Barts Health NHS Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2747","authenticated-orcid":false,"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"Hematology, Citt\u00e0 della Salute e della Scienza Hospital and University, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-2786","authenticated-orcid":false,"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[{"name":"Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance (CHIMOMO), University of Modena and Reggio Emilia, Modena, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"issue":"9","key":"2021072215244335300_B1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","article-title":"Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma","volume":"129","author":"Lunning","year":"2017","journal-title":"Blood"},{"key":"2021072215244335300_B2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-99716-2_5","article-title":"Angioimmunoblastic T-cell lymphoma","volume":"176","author":"Yabe","year":"2019","journal-title":"Cancer Treat Res"},{"issue":"9","key":"2021072215244335300_B3","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2021072215244335300_B4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2021072215244335300_B5","first-page":"549","article-title":"Clonal gene rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy","volume":"133","author":"Feller","year":"1988","journal-title":"Am J Pathol"},{"issue":"3","key":"2021072215244335300_B6","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1182\/blood.V72.3.1000.bloodjournal7231000","article-title":"Clinicopathologic, immunophenotypic, and immunogenotypic analyses of immunoblastic lymphadenopathy-like T-cell lymphoma","volume":"72","author":"Tobinai","year":"1988","journal-title":"Blood"},{"issue":"20","key":"2021072215244335300_B7","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2021072215244335300_B8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.humpath.2005.05.008","article-title":"CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry","volume":"36","author":"Yuan","year":"2005","journal-title":"Hum Pathol"},{"issue":"4","key":"2021072215244335300_B9","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"2021072215244335300_B10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V79.7.1789.1789","article-title":"Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma","volume":"79","author":"Weiss","year":"1992","journal-title":"Blood"},{"issue":"7","key":"2021072215244335300_B11","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/blood.V80.7.1804.1804","article-title":"Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type","volume":"80","author":"Anagnostopoulos","year":"1992","journal-title":"Blood"},{"issue":"6","key":"2021072215244335300_B12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","article-title":"Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases","volume":"138","author":"Willenbrock","year":"2007","journal-title":"Br J Haematol"},{"issue":"25","key":"2021072215244335300_B13","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2021072215244335300_B14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"2021072215244335300_B15","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"issue":"18","key":"2021072215244335300_B16","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2021072215244335300_B17","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d\u2019Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021072215244335300_B18","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"19","key":"2021072215244335300_B19","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2021072215244335300_B20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"23","key":"2021072215244335300_B21","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study [published correction appears in J Clin Oncol. 2016;34(12):1430]","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"2021072215244335300_B22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"2021072215244335300_B23","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2021072215244335300_B24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans Automat Contr"},{"issue":"2","key":"2021072215244335300_B25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/sim.4780030207","article-title":"Regression modelling strategies for improved prognostic prediction","volume":"3","author":"Harrell","year":"1984","journal-title":"Stat Med"},{"issue":"1","key":"2021072215244335300_B26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5581\/1516-8484.20120013","article-title":"T-cell lymphomas in South America and Europe","volume":"34","author":"Bellei","year":"2012","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"9","key":"2021072215244335300_B27","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study [published correction appears in Cancer. 2019;125(21):3893]","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"issue":"10","key":"2021072215244335300_B28","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2021072215244335300_B29","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.bbmt.2015.12.004","article-title":"Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the relapsed\/refractory setting: a systematic review\/meta-analysis","volume":"22","author":"El-Asmar","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2021072215244335300_B30","doi-asserted-by":"crossref","first-page":"12907","DOI":"10.1038\/s41598-018-31212-z","article-title":"B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma","volume":"8","author":"Shang","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"2021072215244335300_B31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/hon.2687","article-title":"Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma","volume":"37","author":"Wudhikarn","year":"2019","journal-title":"Hematol Oncol"},{"issue":"5","key":"2021072215244335300_B32","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"issue":"10168","key":"2021072215244335300_B33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"2021072215244335300_B34","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2021072215244335300_B35","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2021072215244335300_B36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"9","key":"2021072215244335300_B37","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2021072215244335300_B38","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","article-title":"T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma","volume":"4","author":"Ghione","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2021072215244335300_B39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/17474086.2020.1711732","article-title":"Targeting epigenetic regulators in the treatment of T-cell lymphoma","volume":"13","author":"Ahmed","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"21","key":"2021072215244335300_B40","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"issue":"17","key":"2021072215244335300_B41","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O\u2019Connor","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2021072215244335300_B42","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2021072215244335300_B43","first-page":"39","article-title":"Final analysis of the Ro-CHOP phase III study (conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma","volume":"136","author":"Bachy","year":"2020","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/3\/213\/1814765\/bloodbld2020010387.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/3\/213\/1814765\/bloodbld2020010387.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T11:25:14Z","timestamp":1626953114000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/3\/213\/475653\/Outcomes-and-prognostic-factors-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,30]]},"published-print":{"date-parts":[[2021,7,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020010387","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}